You can buy or sell Albireo Pharma and other stocks, options, ETFs, and crypto commission-free!
Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. It pipeline products include Odevixibat, A3384, and Elobixibat. Read More The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
52 Week High
52 Week Low
— per share
Expected Aug 6, Pre-Market